MOMETASONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H28Cl2O4
Molecular Weight	427.361
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 8
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl

InChI

InChIKey=QLIIKPVHVRXHRI-CXSFZGCWSA-N

InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C22H28Cl2O4
Molecular Weight	427.361
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	8 / 8
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00764
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019796s026lbl.pdf

Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. When glucocorticoids are discontinued, asthma stability may persist for several days or longer. Mometasone has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. Mometasone inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis. ELOCON Lotion (Mometasone) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: http://www.drugbank.ca/drugs/DB00764	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Dermatoses 23 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019796s026lbl.pdf	Primary		Approved 8583	ELOCON Approved Use ELOCON Lotion is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients ≥12 years of age. Launch Date 1987
Asthma 244 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021067s013lbl.pdf	Preventing		Approved 8583	ASMANEX Approved Use ASMANEX TWISTHALER is a corticosteroid indicated for: • Maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older. Launch Date 2005

C_max

Value	Dose	Analyte	Population
64.8 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33771722/	400 μg single, respiratory dose: 400 μg route of administration: Respiratory experiment type: SINGLE co-administered:	MOMETASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10.6 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33771722/	800 μg single, respiratory dose: 800 μg route of administration: Respiratory experiment type: SINGLE co-administered:	MOMETASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
86.4 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33771722/	800 μg 1 times / day steady-state, respiratory dose: 800 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:	MOMETASONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
183 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26845343	320 μg 1 times / day steady-state, respiratory dose: 320 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:	MOMETASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.56 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29669668	100 μg single, nasal dose: 100 μg route of administration: Nasal experiment type: SINGLE co-administered:	MOMETASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
924 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33771722/	400 μg single, respiratory dose: 400 μg route of administration: Respiratory experiment type: SINGLE co-administered:	MOMETASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
386 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33771722/	800 μg single, respiratory dose: 800 μg route of administration: Respiratory experiment type: SINGLE co-administered:	MOMETASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
386 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33771722/	800 μg 1 times / day steady-state, respiratory dose: 800 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:	MOMETASONE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1560 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26845343	320 μg 1 times / day steady-state, respiratory dose: 320 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered:	MOMETASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
92 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29669668	100 μg single, nasal dose: 100 μg route of administration: Nasal experiment type: SINGLE co-administered:	MOMETASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
13.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33771722/	400 μg single, respiratory dose: 400 μg route of administration: Respiratory experiment type: SINGLE co-administered:	MOMETASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
18.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33771722/	800 μg single, respiratory dose: 800 μg route of administration: Respiratory experiment type: SINGLE co-administered:	MOMETASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
19.24 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29669668	100 μg single, nasal dose: 100 μg route of administration: Nasal experiment type: SINGLE co-administered:	MOMETASONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
1.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020762s053lbl.pdf			MOMETASONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C8 1057	BCRP 697 P-gp 2052

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2C8 1117	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15601807/ Page: 6.0	yes [IC50 0.327 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16442095/	likely
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/16442095/	likely
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205641Orig1s000ClinPharmR.pdf#page=22 Page: 22,23	yes	unlikely (co-administration study) Comment: ketoconazole 200 mg (as well as placebo) were given twice daily concomitantly on Days 4 to 9. Mometasone furoate plasma concentrations were <150 pcg/mL on Day 3 prior to coadministration of ketoconazole or placebo. Following concomitant administration of ketoconazole, 4 out of 12 subjects in the ketoconazole treatment group (n=12) had peak plasma concentrations of mometasone furoate >200 pcg/mL on Day 9 (211-324 pcg/mL) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205641Orig1s000ClinPharmR.pdf#page=22 Page: 22,23

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:6970	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6970
ZINC	ZINC000004097440	http://zinc15.docking.org/substances/ZINC000004097440

PubMed

Title	Date	PubMed
Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire.	2010-02	19941078
Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial.	2009-12-16	20015903
Allergic contact dermatitis to inhalation corticosteroids.	2009-10-15	19825528
Drugs associated with more suicidal ideations are also associated with more suicide attempts.	2009-10-02	19798416
Treatment of postviral olfactory loss with glucocorticoids, Ginkgo biloba, and mometasone nasal spray.	2009-10	19841338
Alitretinoin--its use in intractable hand eczema and other potential indications.	2009-09-21	19920921
A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care.	2009-08	19671372
Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children.	2009-08	19618993
Effect of the inhaled corticosteroid mometasone on small airway patency in patients with asthma.	2009-06-25	19549430
Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale.	2009-05-27	19479084
Use of mometasone furoate to prevent polyp relapse after endoscopic sinus surgery.	2009-03	19289710
Using nasal steroids to treat nasal obstruction caused by adenoid hypertrophy: does it work?	2009-02	19201278
Inhaled corticosteroids for asthma: are they all the same?	2009-02	19125898
Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control.	2009-01-02	19121204
Local cytokines and clinical symptoms in children with allergic rhinitis after different treatments.	2009	19851472
Comparison of corticosteroid nasal sprays in relation to concomitant use and cost of other prescription medications to treat allergic rhinitis symptoms: retrospective cohort analysis of pharmacy claims data.	2009	19591513
Bronchial diffusing capacity of nitric oxide is increased in patients with allergic rhinitis.	2009	18802360
Mometasone furoate in the management of asthma: a review.	2008-12	19337427
Foxp3+ T regulatory cells (Tregs) are increased in nasal polyps (NP) after treatment with intranasal steroid.	2008-12	18793874
One-year treatment with mometasone furoate in chronic obstructive pulmonary disease.	2008-11-13	19014549
Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis.	2008-10	19209282
Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study.	2008-09-02	18765444
Effect of allergic rhinitis on the use and cost of health services by children with asthma.	2008-08-30	18729293
Long-term follow-up of children undergoing topical intranasal steroid therapy for adenoidal hypertrophy.	2008-08	18499270
Chronic hypokalemia due to excessive cola consumption: a case report.	2008-07-14	18625064
Relative oral corticosteroid-sparing effect of 7 inhaled corticosteroids in chronic asthma: a meta-analysis.	2008-07	18681088
[The effect of desloratadine on quality of life of patients with seasonal allergic rhinitis].	2008-05	18720881
Antibacterial activity of mometasone furoate.	2008-05	18490574
New treatment options in allergic rhinitis: patient considerations and the role of ciclesonide.	2008-04	18728855
New approaches to managing asthma: a US perspective.	2008-04	18728834
Expression of chloride channel protein CLC-3 in patients with allergic rhinitis: effect of topical corticosteroid treatment.	2008-03	18347257
A prospective clinical review of "multi model" approach for treating ear keloids.	2008-01	19753193
[Patient preference survey on the lack of taste and odor of Nasonex nasal spray. Which impact on compliance to treatment?].	2008	18777767
Airways inflammation and treatment during acute exacerbations of COPD.	2008	18686731
Vancomycin-induced DRESS syndrome in a female patient.	2008	18607115
Comparative adrenocortical suppression in dogs with otitis externa following topical otic administration of four different glucocorticoid-containing medications.	2008	18597249
Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate.	2007-11-24	18034980
Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber.	2007-09-22	17882923
Synergistic effect of formoterol and mometasone in a mouse model of allergic lung inflammation.	2007-09	17618304
Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate.	2007-07-25	17650349
Seborrhoeic dermatitis.	2007-07-01	19454093
Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir.	2007-07	17535841
Montelukast in the management of allergic rhinitis.	2007-06	18360641
The role of mometasone furoate aqueous nasal spray in the treatment of adenoidal hypertrophy in the pediatric age group: preliminary results of a prospective, randomized study.	2007-06	17533178
Future therapeutic treatment of COPD: struggle between oxidants and cytokines.	2007	18229560
Eosinophilic airway inflammation in COPD.	2006	18046901
Cough and its importance in COPD.	2006	18046867
The benefits of combined treatment with corticosteroids and long-acting beta agonists.	2006	18046857
Pharmacological treatment of chronic obstructive pulmonary disease.	2006	18044097
Efficacy and safety of ketotifen eye drops as adjunctive therapy to mometasone nasal spray in subjects with seasonal allergic rhinoconjunctivitis.	2003	17535073

Patents

Sample Use Guides

In Vivo Use Guide

Apply a few drops to the affected skin areas once daily and massage lightly until it disappears.

Route of Administration: Topical

In Vitro Use Guide

Mac-1 expression and human eosinophil migration were effectively downregulated by preincubation with Mometasone at 1, 10 and 100 nM

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:07:33 GMT 2025` Edited by `admin` on `Mon Mar 31 18:07:33 GMT 2025`
Record UNII	8HR4QJ6DW8
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MOMETASONE

Official Name

English

MONOVO

Preferred Name

English

LAS-41002

Code

English

9,21-DICHLORO-11.BETA.,17-DIHYDROXY-16.ALPHA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE

Systematic Name

English

LAS41002

Code

English

MOMETASONE [VANDF]

Common Name

English

mometasone [INN]

Common Name

English

(+)-MOMETASONE

Common Name

English

MOMETASONE FUROATE IMPURITY G [EP IMPURITY]

Common Name

English

PREGNA-1,4-DIENE-3,20-DIONE, 9,21-DICHLORO-11,17-DIHYDROXY-16-METHYL-, (11.BETA.,16.ALPHA.)-

Systematic Name

English

Mometasone [WHO-DD]

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 524.957